Civica, the nonprofit generic drug manufacturer that health systems created in response to drug shortages, owes 340B covered entities refunds for overcharges on 13 NDCs from April 13, 2020 through Feb. 23, 2021.
Civica posted a public notice this week about the availability of the refunds on the U.S. Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA) website. “Civica has determined the amount owed to each affected covered entity and intends to refund that amount in the form of a credit,” the notice says. “Separate memos will be sent regarding the credit and the applicable NDCs.”
Civica, the nonprofit generic drug manufacturer that health systems created in response to drug shortages, owes 340B covered entities refunds for overcharges on 13 NDCs from April 13, 2020 through Feb. 23, 2021.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.